Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.
about
Computational systems biology approaches to anti-angiogenic cancer therapeutics.VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomyThe VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk.Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies.Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy.Tumor angiogenesis revisited: Regulators and clinical implications.Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.A critical review on ramucirumab in the treatment of advanced urothelial cancer.Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
P2860
Q35108084-642FB602-66FF-45CC-B0F5-08373DA9D1C5Q35585704-3E063AAF-604E-4C51-981A-10ED5E078616Q37502192-2F396B59-048F-4953-AA35-11FA8B66EBD9Q37632167-BED9D5CB-35CB-457D-A063-5D7B639C0D43Q39000232-1D089A81-66E0-4B8C-9345-994D9838F821Q39393740-1F9D84E7-D919-41D4-AF2A-E49C0C26459FQ45053173-9EAD648A-4FD0-4164-BA66-39CE745BED1FQ47787312-B52CB1C2-BCE5-4EB3-A68A-39560477FB2CQ51402046-49B23BE7-1A5D-4988-8D8D-5E931C427F90
P2860
Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Icrucumab, a fully human monoc ...... malignancies: a Phase 1 study.
@en
Icrucumab, a fully human monoc ...... malignancies: a Phase 1 study.
@nl
type
label
Icrucumab, a fully human monoc ...... malignancies: a Phase 1 study.
@en
Icrucumab, a fully human monoc ...... malignancies: a Phase 1 study.
@nl
prefLabel
Icrucumab, a fully human monoc ...... malignancies: a Phase 1 study.
@en
Icrucumab, a fully human monoc ...... malignancies: a Phase 1 study.
@nl
P2093
P2860
P1476
Icrucumab, a fully human monoc ...... malignancies: a Phase 1 study.
@en
P2093
Aruna Dontabhaktuni
Dmitri Grebennik
Hagop Youssoufian
Nancy Hall
Patricia M LoRusso
Scot Remick
Smitha Krishnamurthi
P2860
P2888
P304
P356
10.1007/S10637-013-9998-8
P577
2013-08-01T00:00:00Z